자동 인슐린 전달 시스템 시장 : 제품 유형별, 컴포넌트별, 인슐린 유형별, 기술별, 당뇨병 유형별, 의료 현장별, 최종사용자별, 유통 채널별 - 시장 예측(2026-2032년)

The Automated Insulin Delivery System Market was valued at USD 990.29 million in 2025 and is projected to grow to USD 1,085.19 million in 2026, with a CAGR of 10.09%, reaching USD 1,942.07 million by 2032.

A comprehensive introduction outlining how integrated sensing, advanced control algorithms, and device ergonomics are redefining clinical and commercial expectations for automated insulin delivery

Automated insulin delivery systems are reshaping diabetes management by integrating continuous glucose sensing, adaptive control algorithms, and automated insulin delivery to reduce day-to-day burden and improve glycemic stability. Recent device generations have moved beyond component-level improvements to a systems-level approach, where sensor fidelity, algorithm sophistication, and pump ergonomics converge to create closed-loop experiences that respond dynamically to physiologic variability. This trajectory reflects decades of incremental innovation combined with accelerated digital health adoption.

Clinicians and health systems increasingly evaluate these platforms not solely on isolated metrics but on how they affect patient-centered outcomes, workflow integration, and long-term adherence. Meanwhile, software-driven control strategy advances enable smoother glycemic trajectories and richer telehealth-enabled touchpoints. As a result, product differentiation has shifted toward interoperability, user experience design, and data security rather than mechanical actuator performance alone.

Taken together, these developments have expanded the dialogue around automated delivery from a purely engineering challenge to a multidisciplinary implementation task. Stakeholders must therefore consider clinical protocols, reimbursement pathways, patient education, and the evolving regulatory environment as core elements of any deployment strategy.

An in-depth exploration of the converging technological, regulatory, and user-experience forces that are driving accelerated evolution across the automated insulin delivery landscape

The landscape for automated insulin delivery is experiencing transformative shifts driven by converging technological, clinical, and commercial forces. Advancements in continuous glucose monitoring have improved signal stability and reduced lag time, enabling control algorithms to make more reliable dosing decisions. At the same time, algorithmic approaches have diversified from rule-based heuristics to predictive and adaptive models that incorporate variability in meal behavior, exercise, and stress responses. This evolution enhances safety margins while also enabling personalization at the individual patient level.

On the commercial side, user experience design and form-factor innovation are increasing adoption by addressing adherence barriers such as device visibility, insertion discomfort, and device maintenance burden. Interoperability frameworks and open protocol initiatives are encouraging modular ecosystems in which pumps, sensors, and software can be combined in new configurations. Concurrently, regulatory agencies are developing clearer pathways for software and algorithm updates, which supports iterative improvement cycles after initial approval. These shifts collectively move the field from siloed product launches toward ecosystem orchestration where clinical outcomes, patient satisfaction, and operational integration determine long-term success.

A strategic examination of the cumulative operational and supply chain consequences stemming from the United States tariff regime introduced in 2025 and how stakeholders can adapt

The imposition of new tariffs and trade policies in the United States in 2025 has created tangible operational and strategic implications for manufacturers, distributors, and healthcare purchasers involved with automated insulin delivery systems. While tariffs typically manifest as increased landed costs for hardware components and finished devices, their broader effects can cascade through supply chain design, sourcing decisions, and product roadmaps. Organizations with lean, geographically concentrated supply chains are more exposed to cost volatility, whereas those with diversified procurement strategies can preserve margin and maintain pricing flexibility.

From a sourcing perspective, tariffs incentivize nearshoring and suppliers' regionalization, especially for critical components such as sensor materials, semiconductor chips used in control electronics, and specialized pump actuators. This shift alters supplier negotiation dynamics and may accelerate investments in local manufacturing capacity, certification, and quality assurance processes. Regulatory and procurement teams must also anticipate changes in vendor evaluation criteria, including total landed cost, lead-time reliability, and resilience to future trade policy shifts.

Clinicians and health systems may experience slower product refresh cycles in some segments if manufacturers defer non-essential launches to manage cost pressures. At the same time, software-centric features that require fewer physical inputs can gain relative prominence as a cost-effective way to differentiate offerings. Overall, the tariff environment reframes strategic priorities toward supply chain resilience, modular product architectures, and collaborations that mitigate exposure to trade disruptions.

Comprehensive segmentation-driven insights that connect product architectures, component choices, insulin formulations, connectivity standards, care contexts, and distribution strategies into actionable commercial intelligence

Insightful segmentation reveals how product design choices and end-use contexts shape clinical value propositions and commercialization strategies for automated insulin delivery systems. Based on product type, platforms vary from fully closed loop systems that aim to minimize manual input to hybrid closed loop configurations that blend automated basal adjustments with user-led boluses; within hybrid solutions, control approaches span fuzzy logic, model predictive control, and proportional integral derivative techniques, each delivering different trade-offs between responsiveness and stability. Sensor-augmented pumps and threshold suspend pumps remain relevant in specific clinical niches where cost, familiarity, or regulatory constraints influence selection.

Component-level distinctions further define capability and integration pathways. Continuous glucose monitors provide either flash monitoring or real-time telemetry, control algorithm software may be deployed via cloud-hosted services or mobile-based applications, and pumps appear as patch or tubed variants that appeal to divergent user preferences. Insulin type selection-from rapid-acting agents such as aspart, glulisine, and lispro to regular U100 and ultra-rapid formulations like Fiasp and Lyumjev-affects pharmacodynamic matching with control algorithms and post-prandial glycemic outcomes.

Technology modalities including Bluetooth implementations (with newer BLE 5.0 or legacy BLE variants), cellular connectivity, and WiFi options (operating on 2.4 GHz or 5 GHz bands) shape remote monitoring, firmware update cadence, and cybersecurity considerations. Diabetes type matters to clinical targeting: gestational populations present unique safety thresholds, Type 1 cohorts subdivide into juvenile onset and late autoimmune presentations, and Type 2 groups separate into insulin-dependent and non-insulin-dependent categories with differing support needs. Care settings-ranging from inpatient environments like general wards and intensive care units to outpatient clinics such as ambulatory daycare and specialty centers-define protocol complexity and device oversight levels. End users include ambulatory services, clinics, homecare environments with adult and pediatric distinctions, and hospitals encompassing ambulatory surgical centers and inpatient units, while distribution channels split between offline pharmacy and online pharmacy routes that influence access, reimbursement, and patient education models.

Together, these segmentation axes clarify where incremental innovation will yield the most clinical and commercial ROI, and where integration, regulatory alignment, and human factors engineering demand priority attention.

Regionally nuanced insights outlining how reimbursement systems, regulatory frameworks, supply chain realities, and cultural factors influence automated insulin delivery penetration across major global regions

Regional dynamics continue to shape adoption pathways, reimbursement models, and regulatory approaches for automated insulin delivery systems across major global markets. In the Americas, clinical practice patterns and payer structures drive demand for integrated solutions that demonstrate clear improvements in patient outcomes and resource utilization; meanwhile, private and public procurement mechanisms influence channel strategies and the balance between capital procurement and service-based models. Transitioning from the Americas to Europe, Middle East & Africa, regulatory harmonization efforts and national health technology assessment frameworks create differentiated pathways to adoption, where local clinical guidelines and reimbursement thresholds affect the timing and breadth of coverage. In these regions, interoperability and data governance emerge as central considerations for cross-border data sharing and multisite deployments.

Asia-Pacific markets present a heterogeneous landscape, where rapid urbanization, expanding diabetes prevalence, and growing digital health ecosystems create both opportunities and implementation challenges. Local manufacturing capacity and regional supply chain policies influence device availability and cost structures, while cultural factors and health system organization impact patient education, device acceptance, and care delivery models. Across all regions, the interplay between local regulatory policy, reimbursement environments, and healthcare infrastructure determines which commercial approaches-direct-to-patient distribution, pharmacy partnerships, or hospital procurement-will be most effective. Regional leaders thus need tailored go-to-market strategies that align with national reimbursement priorities, provider training pathways, and patient support needs.

Key company-level intelligence describing how strategic partnerships, interoperability, clinical validation, and vertical integration are shaping competitive positioning and long-term differentiation

Companies operating in the automated insulin delivery space are increasingly differentiating through a mix of platform integration, software innovation, and strategic partnerships. Market leaders prioritize interoperability, building ecosystems in which sensors, pumps, and algorithm software can communicate seamlessly and adapt to users' changing needs through over-the-air updates and data-driven optimization. At the same time, new entrants focus on niche value propositions such as simplified patch-based pumps, highly accurate sensor chemistries, or algorithmic personalization to capture underserved segments.

Partnership strategies range from component supply agreements to clinical collaborations with academic centers and health systems, accelerating validation cycles and adoption. Investment in cybersecurity, data privacy, and regulatory compliance has become a competitive imperative because digital features now represent critical performance attributes. Organizations that secure strong clinical evidence, robust real-world outcomes, and streamlined integration with electronic health records will achieve durable differentiation. Moreover, vertical integration-spanning from insulin formulation partnerships to device manufacturing and software services-can reduce dependency on external suppliers and enable tighter control over user experience, although it requires substantial capital and cross-disciplinary capabilities.

In this evolving environment, companies that balance product excellence with operational resilience, evidence generation, and customer-centric service models are best positioned to capture long-term clinical and commercial value.

Actionable recommendations aimed at helping manufacturers, payers, and health systems strengthen supply resilience, clinical evidence, user experience, and commercial models for automated insulin delivery

Industry leaders can take concrete steps to secure competitive advantage, accelerate adoption, and mitigate operational risks across the automated insulin delivery value chain. First, strengthening supply chain resilience through strategic diversification, regional supplier qualification, and dual-sourcing of critical components reduces exposure to trade policy shocks and manufacturing disruptions. Second, prioritizing modular product designs that allow sensor, pump, and software components to interoperate eases regulatory complexity and shortens time-to-market for incremental improvements.

Third, investing in rigorous clinical evidence generation-including real-world studies across diverse populations and care settings-builds payer confidence and supports reimbursement discussions. Fourth, enhancing user experience through human factors research, simplified onboarding, and targeted education programs improves adherence and clinical outcomes, particularly among pediatric and geriatric cohorts. Fifth, embracing transparent data governance, robust cybersecurity measures, and clear update pathways for algorithms fosters trust among clinicians and patients while meeting regulatory expectations. Finally, exploring flexible commercial models, such as bundled service offerings, subscription plans for software updates, and pharmacy partnerships for distribution, can align pricing with perceived value and expand access. Implementing these recommendations in an integrated manner will help organizations reconcile clinical priorities with commercial realities and long-term sustainability.

Transparent explanation of the multi-method research approach integrating clinician interviews, regulatory review, technical analysis, and scenario mapping to validate insights and ensure reproducibility

The research underpinning this executive summary employed a multi-method approach designed to capture technology, clinical, regulatory, and commercial dynamics relevant to automated insulin delivery systems. Primary qualitative inputs included structured interviews with clinicians across endocrinology and acute care, procurement leads from hospitals and clinics, device engineers, and patient advocates to surface usability considerations and adoption barriers. Secondary sources comprised peer-reviewed clinical literature, regulatory guidance documents, patent filings, and technical white papers to characterize technological trajectories and safety considerations.

Analytical methods included cross-sectional mapping of product feature sets against clinical use cases, scenario analyses to explore supply chain and policy risks, and triangulation of interview findings with published evidence to validate thematic insights. Attention was given to distinguishing between hardware-driven constraints and software-enabled opportunities, as well as to documenting regional regulatory nuances. Quality assurance processes encompassed source verification, expert peer review, and sensitivity checks to ensure that conclusions reflect robust convergent evidence rather than single-source assumptions. The methodology prioritized transparency and reproducibility while acknowledging limits such as rapidly evolving regulatory decisions and proprietary data gaps that can affect granular product-level interpretation.

A concise concluding synthesis that integrates technological progress, clinical priorities, regional dynamics, and operational imperatives to guide strategic decision-making

In summary, automated insulin delivery systems stand at the intersection of technological innovation, clinical practice transformation, and shifting commercial dynamics. Improvements in sensor accuracy, diversified control algorithms, and refined pump form factors are converging to deliver more patient-centric solutions, while regional policy, reimbursement, and supply chain realities continue to shape adoption pathways. The 2025 tariff environment reframed procurement and sourcing priorities, nudging companies toward regionalization, modularity, and software-led differentiation.

For stakeholders, the immediate imperatives are clear: invest in interoperable architectures, generate robust clinical evidence across diverse populations and care settings, and design user experiences that account for real-world adherence challenges. At the same time, organizations must bolster supply chain resilience and pursue pragmatic commercial models that align incentives across patients, providers, and payers. By integrating technical excellence with evidence-driven deployment and resilient operations, the automated insulin delivery ecosystem can sustain innovation while expanding access and improving patient outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Automated Insulin Delivery System Market, by Product Type

• 8.1. Fully Closed Loop
• 8.2. Hybrid Closed Loop
  • 8.2.1. Fuzzy Logic
  • 8.2.2. Model Predictive Control
  • 8.2.3. Proportional Integral Derivative
• 8.3. Sensor Augmented Pump
• 8.4. Threshold Suspend Pump

9. Automated Insulin Delivery System Market, by Component

• 9.1. Continuous Glucose Monitor
  • 9.1.1. Flash Monitoring
  • 9.1.2. Real Time
• 9.2. Control Algorithm Software
  • 9.2.1. Cloud Based
  • 9.2.2. Mobile Based
• 9.3. Pump
  • 9.3.1. Patch Pump
  • 9.3.2. Tubed Pump

10. Automated Insulin Delivery System Market, by Insulin Type

• 10.1. Rapid Acting
  • 10.1.1. Aspart
  • 10.1.2. Glulisine
  • 10.1.3. Lispro
• 10.2. Regular U100
• 10.3. Ultra Rapid
  • 10.3.1. Fiasp
  • 10.3.2. Lyumjev

11. Automated Insulin Delivery System Market, by Technology

• 11.1. Bluetooth Based
  • 11.1.1. BLE 5.0
  • 11.1.2. Legacy BLE
• 11.2. Cellular Based
• 11.3. WiFi Based
  • 11.3.1. 2.4 GHz
  • 11.3.2. 5 GHz

12. Automated Insulin Delivery System Market, by Diabetes Type

• 12.1. Gestational
• 12.2. Type 1
  • 12.2.1. Juvenile Onset
  • 12.2.2. Late Autoimmune
• 12.3. Type 2
  • 12.3.1. Insulin Dependent
  • 12.3.2. Non Insulin Dependent

13. Automated Insulin Delivery System Market, by Care Setting

• 13.1. Inpatient
  • 13.1.1. General Ward
  • 13.1.2. Intensive Care Unit
• 13.2. Outpatient
  • 13.2.1. Ambulatory Daycare
  • 13.2.2. Specialty Clinic

14. Automated Insulin Delivery System Market, by End User

• 14.1. Ambulatory
• 14.2. Clinics
• 14.3. Homecare
  • 14.3.1. Adult Users
  • 14.3.2. Pediatric Users
• 14.4. Hospital
  • 14.4.1. Ambulatory Surgical Centers
  • 14.4.2. Inpatient

15. Automated Insulin Delivery System Market, by Distribution Channel

• 15.1. Offline Pharmacy
• 15.2. Online Pharmacy

16. Automated Insulin Delivery System Market, by Region

• 16.1. Americas
  • 16.1.1. North America
  • 16.1.2. Latin America
• 16.2. Europe, Middle East & Africa
  • 16.2.1. Europe
  • 16.2.2. Middle East
  • 16.2.3. Africa
• 16.3. Asia-Pacific

17. Automated Insulin Delivery System Market, by Group

• 17.1. ASEAN
• 17.2. GCC
• 17.3. European Union
• 17.4. BRICS
• 17.5. G7
• 17.6. NATO

18. Automated Insulin Delivery System Market, by Country

• 18.1. United States
• 18.2. Canada
• 18.3. Mexico
• 18.4. Brazil
• 18.5. United Kingdom
• 18.6. Germany
• 18.7. France
• 18.8. Russia
• 18.9. Italy
• 18.10. Spain
• 18.11. China
• 18.12. India
• 18.13. Japan
• 18.14. Australia
• 18.15. South Korea

19. United States Automated Insulin Delivery System Market

20. China Automated Insulin Delivery System Market

21. Competitive Landscape

• 21.1. Market Concentration Analysis, 2025
  • 21.1.1. Concentration Ratio (CR)
  • 21.1.2. Herfindahl Hirschman Index (HHI)
• 21.2. Recent Developments & Impact Analysis, 2025
• 21.3. Product Portfolio Analysis, 2025
• 21.4. Benchmarking Analysis, 2025
• 21.5. Abbott Laboratories
• 21.6. Beta Bionics, Inc.
• 21.7. Bigfoot Biomedical, Inc.
• 21.8. CamDiab Ltd
• 21.9. Cellnovo Group Ltd
• 21.10. Dexcom, Inc.
• 21.11. Diabeloop SAS
• 21.12. DreaMed Diabetes Ltd
• 21.13. Eli Lilly and Company
• 21.14. EoFlow Limited
• 21.15. F. Hoffmann-La Roche Ltd
• 21.16. Insulet Corporation
• 21.17. Medtronic plc
• 21.18. Medtrum Technology, Inc.
• 21.19. Novo Nordisk A/S
• 21.20. Senseonics Holdings, Inc.
• 21.21. Sooil Development Co., Ltd
• 21.22. Tandem Diabetes Care, Inc.
• 21.23. TypeZero Technologies, Inc.
• 21.24. Ypsomed AG